Home » News » Drug Sponsors » WuXi Revenues Up 98%, Still Fall Short

WuXi Revenues Up 98%, Still Fall Short

Thursday, November 13, 2008

WuXi Pharmatech released final third quarter earnings that reflected 98% revenue growth year-over-year but fell short of the company’s projected Q3 earnings.

Net revenues for the quarter were $67.5 million, down from the $74 million originally forecast. The Chinese contract research organization confirmed its most recent revised full-year revenue guidance of $260 million to $265 million. WuXi share prices dropped 5% to $7.42 in morning trading Thursday.

WuXi also announced this week the signing of a new three-year in vitro ADME collaboration agreement with Pfizer, and, last month, WuXi signed a new R&D collaboration agreement with Johnson & Johnson, expanding the already long-standing relationship between the two companies.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!